Lasma AB 10 Tablets

babies: not applicable. lactating mother: consult your doctor before using this medication during breastfeeding.
pregnancy: consult your doctor before using this medication during pregnancy. driving: acebrophylline, montelukast sodium tablet may reduce your alertness, and it may affect your vision or make you feel dizzy or sleepy.
do not drive if these symptoms occur alcohol: caution is advised when consuming alcohol with acebrophylline, montelukast sodium tablets. consult your doctor.
kidney: acebrophylline, montelukast sodium tablet should be used with caution in patients with kidney disease. dose adjustment is required.
consult your doctor. liver: acebrophylline, montelukast sodium tablet should be used with caution in patients with liver disease.
dose adjustment is required. consult your doctor..

Vomiting Heartburn Stomach pain Rash Itching Hives Drowsiness Breathing problems Increased white blood cell count Nasal Inflammation Flu-like symptoms.

LASMA AB is a mucolytic. it works by making the mucus thin and loose, thereby it helps to cough out easily and makes breathing easier by opening airways.
it is a leukotriene antagonist. it works by blocking the action of a chemical messenger (leukotriene).
hence it reduces inflammation in the nose & airways to prevent allergy symptoms and asthma..

If you miss a dose, take LASMA AB as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• LASMA AB should be taken after food to avoid stomach discomfort • always keep the inhaler with you to relieve sudden breathing problems • Inform your doctor if you have kidney, liver, heart disease, or a history of smoking • monitor blood tests regularly to check the level of drug in the body • medication should not be stopped unless told by your doctor, even if you feel better.

• acebrophylline + reserpine: concurrent use may result in increased heart rate • acebrophylline + phenytoin: concurrent use may result in reduced plasma concentration and decreased effectiveness of acebrophylline • acebrophylline + frusemide: concurrent use may result in increased dieresis • acebrophylline + erythromycin: concurrent use may result in increased plasma concentrations of acebrophylline • montelukast sodium + abametapir: concurrent use may increase the serum concentration of montelukast sodium • montelukast sodium + cladribine: concurrent use may result in increased risk or severity of myopathy, rhabdomyolysis, and myoglobinuria • montelukast sodium + domperidone: concurrent use results in decreased metabolism of montelukast • montelukast sodium + methotrexate: concurrent use may result in an increased risk of myopathy, rhabdomyolysis, and myoglobinuria.